A case of recurrent endometrial cancer with long‐term complete remission following pembrolizumab‐induced severe immune‐related adverse event colitis. Issue 10 (8th July 2022)

• Record Type: Journal Article
• Authors: Yamamoto, Akiko; Nagashima, Takeo; Imai, Yoshinari; Akitsu, Kensuke; Yamanaka, Zenta; Nishi, Hirotaka
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 48:Issue 10(2022)
• Page Start: 2630
• Page End: 2634
• Publication Date: 2022-07-08
• Subjects: anti‐PD‐1 antibody -- endometrial cancer -- immune‐related adverse event -- pembrolizumab -- recurrence; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.15346
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Endometrial cancer is generally diagnosed at an early stage and has a good prognosis, although once it recurs, the prognosis is poor because of few therapeutic options. Since endometrial cancer has a high frequency of microsatellite instability‐high/mismatch repair deficiency, the anti‐PD‐1 antibody pembrolizumab is expected to be one of the key therapeutic agents for recurrent endometrial cancer. Immune‐related adverse events (irAEs) are autoimmune‐like unique and occasionally life‐threatening side effects of immune checkpoint inhibitors. Here, we report a rare case of recurrent endometrial cancer that showed long‐term complete remission after developing relapsing severe irAE colitis following the introduction of pembrolizumab.